Lupus erythematosus - Lupus Eritematosu
☆ In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
Si vede cum'è un eritema ligeramente violaceu.
L'eruzione di farfalla chì tipicamenti appare nantu à a faccia.
References
Identificà è classificà cutaneous lupus erythematosus (CLE) pone sfide diagnostiche, distinguendulu da systemic lupus erythematosus cù implicazione di a pelle. Studi recenti mettenu in luce nantu à i fatturi genetichi, ambientali è immunologichi sottumessi à CLE. L'induzione di droga hè specificamente emersa cum'è unu di i triggers più impurtanti per CLE. U trattamentu implica terapie tematiche è sistemiche, cumpresi biològichi promettenti (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , cù efficacità dimustrata in prucessi clinichi.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) copre diversi prublemi di a pelle, alcuni di i quali puderanu ligà à prublemi di salute più largu. Hè categurizatu in diversi tipi, cum'è acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE comprende discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus hè un gruppu di malatie autoimmune chì ponu influenzà diverse parti di u corpu. Certi tipi, cum'è systemic lupus erythematosus (SLE) , influenzanu parechji organi, mentre chì altri, cum'è cutaneous lupus erythematosus (CLE) , affettanu principalmente a pelle. Avemu categurizà diverse tippi di CLE basatu annantu à una mistura di segni clinichi, esame di tissuti è testi di sangue, ma ci hè assai variazioni trà l'individui. I prublemi di a pelle spessu si sviluppanu per fatturi cum'è l'esposizione à u sole, u fumu, o certi medicazione.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
A causa di lupus eritematosu (lupus erythematosus) ùn hè micca chjaru. Trà i gemelli idèntici, se unu hè affettatu, ci hè una probabilità di 24% chì l'altru sia ancu. L'hormone sessuale femminile, a luce di u sole, u fumu, a carenza di vitamina D, è certe infizzioni sò ancu crede chì aumentanu u risicu.
I trattamenti ponu include NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, è methotrexate. Ancu s'è i corticosteroidi sò efficaci, l'usu à longu andà risultatu in effetti latu.